Sickle Archives - Precision Medicine Group

White Paper: Unleashing the Power of Precision Medicine: Radioligand Therapy

Morgan Labbree2023-11-03T16:36:34-04:00Cell & Gene Therapy, News, Thought Leadership|

This article was originally published on This Month in Transformative Medicine on October 17, 2023

The current standard of cancer care has saved many lives, but these methods often come with incredibly difficult side effects. Advancements in technology have brought new options to cancer care that hope to provide meaningful outcomes while minimizing the impact to the patient’s quality of life.

In this white paper Anshul Mangal, President of Project Farma (PF) & Precision ADVANCE, and Sumit Verma, Co-founder and Partner at Orchestra Life Sciences, discuss the power and potential of radioligand therapies and its impact on the treatment of a number of cancers.

(more…)

On Demand: State of the Union for Advanced Therapies

Morgan Labbree2023-11-14T10:42:38-05:00Cell & Gene Therapy, Events|

Sponsored by Precision ADVANCE, this Endpoints webinar convened industry leaders to discuss the current state of the industry, and the future of advanced therapies including innovations in research and development, going from treating rare diseases to prevalent conditions, continued investment, and next-generation technologies. The panelists also discussed manufacturing and talent bottlenecks, and innovative reimbursement payment models. This discussion was moderated by Anshul Mangal: President (Precision ADVANCE & Project Farma), and included insights from Dan Kirby: Chief Commercial Officer (Orca Bio), Deborah Phippard: CSO (Precision for Medicine), Devyn Smith: CEO (Arbor Bio), Helen Sabzevari: President & CEO (Precigen) and Chad Salisbury: SVP (Project Farma).

(more…)

White Paper: Scaling Hope: The Growth of the Allogeneic Cell Therapy Sector

Morgan Labbree2023-09-22T15:39:39-04:00Cell & Gene Therapy, News, Thought Leadership|

In the rapidly evolving landscape of advanced therapies, allogeneic cell therapies have emerged as a promising avenue for addressing various disorders, including hematological malignancies, neurological conditions, and autoimmune or inflammatory diseases. With a number of clinical trials underway to evaluate their efficacy, allogeneic cell therapies hold significant potential in reshaping the way we approach treating numerous diseases.

In this white paper, Anshul Mangal, President of Project Farma & Precision ADVANCE and John Khoury, Executive Vice President of Project Farma (PF), discuss the growth of the allogeneic cell therapy sector and its impact on patient access.

(more…)

Webinar: Rise of mRNA manufacturing

Morgan Labbree2023-09-13T19:38:47-04:00Cell & Gene Therapy, Events|

Sponsored by Project Farma, a Precision for Medicine Company, this panel will feature insights from industry leaders on the current state of the market for mRNA-based medicines, techniques to optimize manufacturing and technical operations, and strategies for CQV, quality, automation & engineering for mRNA facilities.

This discussion will be moderated by Anshul Mangal: President (Project Farma & Precision ADVANCE), and include insights from Aaron Allen: Director, Global Quality, External Engagement (Moderna), Andrew Geall: Co-founder and Chief Development Officer (Replicate Bioscience), Jane True: Global VP, mRNA Commercial Strategy Innovation & Pandemic Security Lead (Pfizer), Venkata Indurthi: CSO (Aldevron), and Chad Salisbury: SVP (Project Farma).

(more…)

White Paper: Cell and Gene Therapies: How High Can Prices Go?

Morgan Labbree2023-08-11T13:10:02-04:00Cell & Gene Therapy, News, Thought Leadership|

The concept of optimizing CGT value propositions begs the question of what is reasonable when it comes to breakthrough science and unprecedented therapeutic solutions. Can a $5 million price tag be justified? What about $10 million?

This white paper is based on a webinar convened by PRECISIONadvisors, focusing on cell and gene therapy (CGT) pricing. The webinar featured two in-house experts from the PRECISIONadvisors Global Pricing & Market Access practice: Richard Macaulay, Senior Vice President and David Carr, Senior Director.

(more…)

On Demand: The Future of Cell Therapy Development and Delivery

Morgan Labbree2023-08-24T13:19:48-04:00Cell & Gene Therapy, Events|

Sponsored by Precision ADVANCE, this Endpoints webinar convened leading advanced therapy experts to discuss the future of cell therapy development and delivery. This discussion was moderated by John Khoury: EVP (Project Farma), and included insights from Chris McDonald: Global Head of Tech Ops (Kite Pharma), Mark Frattini: CMO (Cellectis), Jason Foster: CEO & ED (Ori Biotech), and Phil Cyr: SVP (Precision Value & Health).

(more…)

Conference: CAR-TCR Summit, 2023

Morgan Labbree2023-07-31T15:37:47-04:00Cell & Gene Therapy, Events, Thought Leadership|

Precision will be at this year’s CAR-TCR Summit August 29 – September 1, 2023, in Boston, MA. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization of cell therapies.

Speaking Engagements
Detailed descriptions for each speaking engagement are included below.

Precision ADVANCE will hold a welcome reception on August 29, 2023, at 5:30 pm.
Project Farma will be facilitating a Manufacturing track panel discussion “Keys to Success for a Commercial – Ready Cell Therapy Facility” on August 30, 2023, 4:30 – 5:00 pm.
Precision ADVANCE will be facilitating an Early-Stage Clinical Strategy track panel discussion “Strategies for Successful Clinical Development of Cell Therapies” on August 30, 2023, 4:30 – 5:00 pm.
Precision ADVANCE will have a plenary speaking position “The Journey of Commercializing Cell Therapies” on August 31, 2023, 8:05 – 8:50 am.

Connect with our Advanced Therapy experts

Visit us at booth 90 in the exhibition area
Schedule in-person or virtual meetings with one of our experts
Attend our ADVANCE-sponsored Welcome Reception on August 29, 2023, at 5:30 PM ET

(more…)

White Paper: mRNA Innovation Is Revolutionizing Disease Prevention

Morgan Labbree2023-11-09T08:12:07-05:00Cell & Gene Therapy, News, Thought Leadership|

The first FDA approved mRNA product was decades in the making, following many iterations throughout history the first mRNA vaccine in the US was brought to life. This achievement delivered aid to patients and healthcare providers during the most critical public health crisis in recent years. Since then, researchers have been operating at incredible speeds to develop more novel mRNA treatment options for patients, across many indications.

In this white paper, Anshul Mangal, President of Project Farma & Precision ADVANCE and Chad Salisbury, Senior Vice President of Project Farma (PF), discuss the mRNA revolution and its impact on the future of disease prevention and treatment.

(more…)

White Paper: Moving Clinical Development Forward in 2023

Morgan Labbree2023-07-24T21:05:36-04:00Cell & Gene Therapy, News, Thought Leadership|

In today’s cell and gene therapy landscape, there are over 1,400 companies striving to move their products forward into clinic—a critical step in commercializing these groundbreaking treatments. Clinical development is a complex endeavor and the path to market requires careful consideration of factors ranging from chemistry, manufacturing, and controls (CMC) and regulatory strategy to study design, CRO selection, and clinical trial diversity.

(more…)

White Paper: The Price is Right: Cell and Gene Therapy Approvals and Market Access in 2023

Morgan Labbree2023-07-24T21:06:01-04:00Cell & Gene Therapy, News, Thought Leadership|

Starting health economic evidence development and market access planning as early as possible in clinical development for a cell and gene therapy is important demonstrating the value to payers and health technology appraisal (HTA) organizations. In a dynamic regulatory and market access landscape, balancing the requirements of regulators and the expectations of payors can be challenging since there is no one-size-fits-all approach.

(more…)